Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 2023 Top 10 Pharma & Biopharma Preview | Contract Pharma

What are you searching for?

Sign in
Online Exclusives

2023 Top 10 Pharma & Biopharma Preview

A by the numbers look into Contract Pharma's Top Companies Report.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The following is a preview of Contract Pharma’s upcoming Top 20 Companies Report based on 2022 Pharmaceutical Rx sales in $U.S. millions. 
(excludes consumer healthcare, medical device, diagnostics division sales)
 
Our annual look at the 20 biggest Pharma and Biopharma players highlights key financials, top selling drugs, acquisitions & alliances, drug approvals, pipeline advances, significant personnel moves, and more. 

1. Pfizer: $100,330 
2. Merck: $59,283 
3. Abbvie: $58,054
4. Roche: $52,650 
5. Johnson & Johnson: $52,563 
6. Novartis $50,545 
7. Bristol Myers Squibb: $46,159 
8. Sanofi $45,899 
9. AstraZeneca: $44,351 
10. GlaxoSmithKline: $35,360 
 
Pfizer
Headcount:~83,000
Revenues: $100,330 (+23%)
Net Income: $31,372 (+43%)
R&D expenses: $11,428 (+10%)
 
Merck
Headcount: 69,000 
Revenues: $59,283 (+22%)
Net Income: $14,519 (+18%) 
R&D expenses: $13,548 (+11%)
 
Abbvie
Headcount: ~50,000
Revenues: $58,054 (+14%)
Net Income: $11,845 (+3%) 
R&D expenses: $6,510 (-6%)
 
Roche 
Headcount: 104,000
Revenues: $71,920 (+1%)
Pharma Revenues: $52,650 (+1%)
Net Income: $14,650 (-9%)
R&D: $17,348 (+8%)
 
Johnson & Johnson
Headcount: 153,000
Revenues: $94,943 (+1%)
Pharma Revenues: $52,563 (+2%)
Net Income: $17,941 (-14%) 
R&D expenses: $14,603 (-1%)
 
Novartis
Headcount: 101,703
Revenues: $50,545 (-2%)
Net Income: $6,955 (-71%) 
R&D expenses: $9,996 (+5%)
 
Bristol Myers Squibb
Headcount: 34,300
Revenues: $46,159 (+3%)
Net Income: $6,345 (-10%)
R&D expenses: $9,509 (-7%)
 
Sanofi
Headcount: 91,573
Revenues: $45,899 (+14%)
Net Income: $7,174 (+8%) 
R&D expenses: $7,159 (+18%) 
 
AstraZeneca
Headcount: 83,500
Revenues: $44,351 (+19%)
Net Income: $3,293 (n/m) 
R&D expenses: $9,762 (flat)
 
GlaxoSmithKline
Headcount: 69,400 
Revenues: $35,360 (+4%)
Net Income: $18,836 (>100%) 
R&D expenses: $6,618 (+9%)

Coming soon, Contract Pharma’s July/August Top 20 Companies Report!
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics